Value of multiparametric magnetic resonance imaging in prostate cancer detection based on#br# prostate imaging reporting and data system version 2
ZENG Hao1, YANG Guo-qing1, FU Quan-shui1, CHEN Hong1, ZHAO Lin-wei1, NIU Xiang-ke2
1.Department of Radiology, Suining Central Hospital, Suining Sichuan 629000, China;
2.Department of Radiology, Affiliated Hospital of Chengdu University, Chengdu 610081, China
Abstract：Objective: To evaluate interobserver agreement and diagnosis value with the use of updated Prostate Imaging Reporting and Data System version 2(PI-RADS v2) for the detection of prostate cancer. Methods: The multiparametric MRI images of 176 histologically proven prostate lesions were analyzed retrospectively. Prostate biopsy was performed under the guidance of TRUS. Biopsied lesions were evaluated according to the PI-RADS v2 and compared with histopathological findings by two observers blindly. Cohen’s Kappa statistics were calculated to evaluate the consistency of the two observers and the area under the receiver operating characteristic curve(ROC-AUC) was calculated to evaluate the diagnosis value of PI-RADS v2. Results: Interobserver agreement for peripheral zone and transition zone lesions were 0.63 and 0.60, respectively. For peripheral zone cancer and transition zone cancer, the sensitivity, specificity, PPV, and NPV were 85%, 79%, 76%, 87% and 81%, 69%, 64%, 72%, respectively. Conclusion: The application of updated PI-RADS v2 provides high interobserver agreement for detecting peripheral zone and transition zone lesions. Futhermore, PI-RADS v2 can achieve relatively high sensitivity and NPV in the diagnosis of peripheral zone cancer. For transition zone cancer, although PI-RADS v2 can achieve relatively high sensitivity, the specificity needs to be improved.
曾 浩1，杨国庆1，付泉水1，陈 洪1，赵林伟1，牛翔科2. 基于PI-RADS v2研究多参数磁共振成像在前列腺癌中的诊断价值[J]. 中国临床医学影像杂志, 2017, 28(1): 60-63.
ZENG Hao1, YANG Guo-qing1, FU Quan-shui1, CHEN Hong1, ZHAO Lin-wei1, NIU Xiang-ke2. Value of multiparametric magnetic resonance imaging in prostate cancer detection based on#br# prostate imaging reporting and data system version 2. JOURNAL OF CHINA MEDICAL IMAGING, 2017, 28(1): 60-63.
[1]Iwazawa J, Mitani T, Sassa S, et al. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging?[J]. Diagn Interv Radiol, 2011, 17(3): 243-248.
[2]Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging[J]. Radiology, 2010, 257(3): 715-723.
[3]Vargas HA, H?觟tker AM, Goldman DA, et al. Updated prostate imaging reporting and data system(PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference[J]. Eur Radiol, 2016, 26(6): 1606-1612.
[4]Barrett T, Turkbey B, Choyke PL. PI-RADS version 2: what you need to know[J]. Clin Radiol, 2015, 70(11): 1165-1176.
[5]Schimm?觟ller L, Quentin M, Arsov C, et al. Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard[J]. Eur Radiol, 2013, 23(11): 3185-3190.
[6]Baur AD, Maxeiner A, Franiel T, et al. Evaluation of the prostate imaging reporting and data system for the detection of prostate cancer by the results of targeted biopsy of the prostate[J]. Invest Radiol, 2014, 49(6): 411-420.
[7]Renard-Penna R, Mozer P, Cornud F, et al. Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy[J]. Radiology, 2015, 275(2): 458-468.
[8]Junker D, Sch?覿fer G, Edlinger M, et al. Evaluation of the PI-RADS scoring system for classifying mpMRI findings in men with suspicion of prostate cancer[J]. Biomed Res Int, 2013, 2013: 252939.
2017, Vol. 28 
